Mia's Feed
Medical News & Research

FDA Warning: Peanuts Detected in Certain Ritz Cracker Sandwiches Prompting Recall

FDA Warning: Peanuts Detected in Certain Ritz Cracker Sandwiches Prompting Recall

Share this article

The FDA has issued a risk warning and recall for certain Ritz cracker sandwiches due to undeclared peanuts, posing a serious allergy risk. Consumers should check labels carefully.

2 min read

The U.S. Food and Drug Administration (FDA) has issued a risk warning concerning specific Ritz cracker sandwich products due to the potential presence of undeclared peanuts, a major allergen. This alert follows a voluntary recall announced by Mondelēz Global LLC on July 8, 2025. The recall affects several product sizes, including the Ritz Peanut Butter Cracker Sandwiches in 8-pack, 20-pack, and 224-case quantities, as well as the Ritz Filled Cracker Sandwich 20-count variety pack.

The recall was initiated after the discovery that packaging films used for wrapping individual peanut butter products may contain defects caused by a supplier error. While the outer cartons were correctly labeled to indicate the presence of peanuts, some individual packs were mislabeled as cheese sandwiches. Consumers with peanut allergies are strongly advised not to consume these products, which could cause serious or life-threatening allergic reactions such as hives, lip swelling, or anaphylaxis.

To date, no injuries or illnesses have been reported. The affected products have specific UPC codes and best-by dates ranging from November 2025 to January 2026. These products were sold nationwide at retail stores.

The allergen labeling error posed a serious health risk to individuals allergic to peanuts, making it crucial for consumers to check product labels carefully. Mondelēz Global LLC has assured that corrective actions are underway to prevent future issues.

For those who purchased these products and have peanut allergies, it is recommended to contact the company at 844-366-1171 for further assistance. Consumers are also encouraged to learn more about peanut allergies through reputable sources such as the American Academy of Allergy, Asthma & Immunology.

Source: https://medicalxpress.com/news/2025-07-ritz-fda-issues-due-undeclared.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

AI-Based Model Reframes Multiple Sclerosis as a Continuous Disease with Dynamic Stages

A new AI-driven study redefines multiple sclerosis as a continuous disease with dynamic stages, moving beyond traditional subtypes. This innovative approach could revolutionize diagnosis and personalized treatment strategies.

Breakthrough Treatments Developed to Prevent Life-Threatening HTLV-1 Virus Infection

Researchers have developed the world's first treatments to prevent the transmission of HTLV-1, a deadly virus affecting millions globally, using existing HIV medications in innovative ways.

Innovative Hospital-Wide Trial Demonstrates Cost-Effective Method for Comparing Intravenous Fluids

A novel hospital-wide trial comparing IV fluids demonstrates a cost-effective and efficient method for large-scale clinical research, paving the way for quicker, resource-friendly medical studies.

Safety and Effectiveness of GLP-1 Receptor Agonists for Obesity Treatment in Adults with Mental Illness

New evidence shows GLP-1 receptor agonists are safe and effective in promoting weight loss and improving metabolic health in adults with mental illness, with no increased risk of adverse psychiatric effects. These medications offer promising benefits for addressing obesity in this vulnerable population.